ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Zai Lab Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.06+0.87 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $26.87B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.23 (−14.95%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Zai Lab Ltd grew revenue 5.1% to $449.61M over the twelve months to Jun 30, 2026. Free cash flow was -$139.57M.
Revenue
$449.61M
+5.1% vs. a year earlier
Operating income
-$264.10M
TTM Q2 2026
Free cash flow
-$139.57M
TTM Q2 2026
EPS, diluted
-$0.18
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $26.87B
- P/E ratio
- –
- Price to sales
- 59.77
- Price to book
- 44.27
- Dividend yield
- –
- Free cash flow yield
- -0.52%
Fundamentals
- Revenue
- $449.61M
- Net income
- -$188.21M
- EPS, diluted
- -$0.18
- Free cash flow
- -$139.57M
- Book value per share
- $0.54
- Diluted shares
- 1.12B
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$449.61M+5.1% YoY
Gross profit
$254.07M-5.2% YoY
Operating income
-$264.10M
Net income
-$188.21M
EPS, diluted
-$0.18
Free cash flow
-$139.57M
Reported periodTrailing twelve months